Table 3.
Comparison of early vs initial medical therapy in Crohn’s disease n (%)
|
Initial medical therapy (n = 115) |
|||||
| Clinical details | Early surgery (n = 42) | Initial medical therapy (n = 115) | P value | Deferred surgery (n = 62)1 | P value |
| Number requiring surgery | |||||
| 3 yr | 5 (11.9) | 24 (20.7) | 0.250 | 5 (8.1) | 0.521 |
| 5 yr | 6 (14.2) | 36 (31.3) | 0.041 | 10 (16.1) | NS |
| Completion of study period | 7 (16.7) | 62 (53.9) | < 0.0001 | 20 (32.3) | 0.110 |
| Number of admission to hospital per patient, median (IQR) | 1 (1-2) | 3 (1-5) | 0.012 | 2 (1-4.5) | 0.002 |
| Days in hospital (d), median (IQR) | 12.5 (9-22.5) | 11 (3-28) | 0.230 | 17 (8-28) | 0.347 |
| Medical therapy | |||||
| Immune modulator | 32 (76.2) | 101 (87.8) | 0.083 | 54 (87.1) | 0.189 |
| Steroids | 12 (28.6) | 34 (29.6) | NS | 23 (37.1) | 0.404 |
| Anti-TNF | 14 (33.3) | 69 (60.0) | 0.004 | 42 (67.7) | 0.001 |
| No requirement for medical therapy | 10 (23.8) | 5 (4.3) | 0.008 | 0 (0) | < 0.0001 |
| Follow-up months (mo), median (IQR) | 67 (31-114) | 97 (58-150) | 64 (19-121) | ||
1
Data for this subset regarding length of stay and hospital admissions was taken from the date of first operation and not from date of diagnosis. IQR: Interquartile range; TNF: Tumour necrosis factor; NS: Not significant.